Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume
Akums invested Rs. 272 crore in capital expenditure during FY25
Subscribe To Our Newsletter & Stay Updated
